Fidaxomicin

Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL) . Fidaxomicin can be used for Clostridium difficile infection (CDI) research[1][2][3].

Product Specifications

CAS Number

[873857-62-6]

Product Name Alternative

OPT-80; PAR-101

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Fidaxomicin.html

Purity

99.85

Solubility

DMSO : ≥ 33 mg/mL

Smiles

O=C(C(C(O)=C(Cl)C(O)=C1Cl)=C1CC)O[C@H]([C@H](O[C@H]2OC/C(C(O[C@](C/C=C3C)([H])[C@H](O)C)=O)=C\C=C\C[C@@H](/C(C)=C\[C@H](CC)[C@@H](O[C@@](OC(C)(C)[C@@H](OC(C(C)C)=O)[C@@H]4O)([H])[C@H]4O)\C(C)=C/3)O)C)[C@@H]([C@@H]2OC)O

Molecular Formula

C52H74Cl2O18

Molecular Weight

1058.04

Precautions

H302, H315, H319, H335

References & Citations

[1]Poxton IR, et al. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010 Apr;5 (4) :539-48.|[2]Tannock GW, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading) . 2010 Nov;156 (Pt 11) :3354-3359.|[3]Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48 (6) :2280-2. |[4]Ackermann G, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48 (6) :2280-2.